Myriad Genetics Inc (MYGN)
Return on equity (ROE)
| Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -155,200 | -234,600 | -263,300 | -274,400 | -248,200 | -146,200 | -112,000 | -77,300 | -17,600 | -8,200 | -27,200 | -34,800 | -114,800 | -225,300 | -194,100 | -199,500 | -148,300 | -26,200 | -15,300 | 4,600 |
| Total stockholders’ equity | US$ in thousands | 740,500 | 760,000 | 783,200 | 683,400 | 735,200 | 835,200 | 885,800 | 916,600 | 947,400 | 950,100 | 967,800 | 968,600 | 902,500 | 875,200 | 909,300 | 918,200 | 967,200 | 1,077,200 | 1,074,500 | 1,088,900 |
| ROE | -20.96% | -30.87% | -33.62% | -40.15% | -33.76% | -17.50% | -12.64% | -8.43% | -1.86% | -0.86% | -2.81% | -3.59% | -12.72% | -25.74% | -21.35% | -21.73% | -15.33% | -2.43% | -1.42% | 0.42% |
June 30, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-155,200K ÷ $740,500K
= -20.96%
Myriad Genetics Inc's Return on Equity (ROE) has exhibited significant fluctuations over the past few quarters. The ROE has ranged from negative 40.15% in September 2023 to a positive 0.42% in December 2019. In the most recent quarter, Jun 30, 2024, the ROE was recorded at -20.96%.
The negative ROE figures indicate that the company's net income is insufficient to cover its shareholders' equity, which may raise concerns about profitability and operational efficiency. The downward trend in ROE from Dec 2021 to Jun 2024 suggests a declining ability of the company to generate profit from its equity base.
Investors and stakeholders may need to closely monitor Myriad Genetics Inc's financial performance and assess the factors contributing to the fluctuations in ROE to make informed decisions about the company's future prospects and financial health.
Peer comparison
Jun 30, 2024